Anika Therapeutics, Inc. (ANIK)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 50M 100M 150M Q3 '24: 86.4M Q4 '24: 119.9M Q1 '25: 117.1M Q2 '25: 114.5M Q3 '25: 112.8M Q4 '25: 112.8M Q1 '26: 116.3M Q2 '26: 120.7M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit TTM

0 30M 60M 90M Q3 '24: 64.6M Q4 '24: 76M Q1 '25: 71.7M Q2 '25: 65.6M Q3 '25: 61.8M Q4 '25: 63.8M Q1 '26: 68.1M Q2 '26: 75M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating Income TTM

-14M -7M 0 7M 14M 21M Q3 '24: 20.3M Q4 '24: -5.1M Q1 '25: -6.9M Q2 '25: -9.2M Q3 '25: -12.4M Q4 '25: -11.1M Q1 '26: -12.3M Q2 '26: -5.1M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income TTM

-105M -70M -35M 0 35M 70M 105M Q3 '24: -97.5M Q4 '24: -56.4M Q1 '25: -56.7M Q2 '25: -60.6M Q3 '25: -33M Q4 '25: -10.9M Q1 '26: -11.1M Q2 '26: -3.8M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue TTM

0 25M 50M 75M Q3 '22: 64.9M Q4 '24: 43.9M Q1 '25: 45.3M Q2 '25: 49M Q3 '25: 51.1M Q4 '25: 49M Q1 '26: 48.1M Q2 '26: 45.6M Q3 '22 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating Cash Flow TTM

0 4M 8M 12M Q3 '24: 7.5M Q4 '24: 5.4M Q1 '25: 5.4M Q2 '25: 6.3M Q3 '25: 8.1M Q4 '25: 11.2M Q1 '26: 6.5M Q2 '26: 6M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow TTM

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q3 '24: -808K Q4 '24: -2.3M Q1 '25: -3.4M Q2 '25: -535K Q3 '25: 648K Q4 '25: 4.4M Q1 '26: 1M Q2 '26: 562K Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 6M 12M 18M Q1 '24: 14.7M Q2 '24: 14.9M Q3 '24: 14.8M Q1 '25: 14.3M Q2 '25: 14.5M Q3 '25: 14.4M Q1 '26: 13.5M Q2 '26: 13.7M Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q3 '24: -6.64 Q4 '24: -3.83 Q1 '25: -3.86 Q2 '25: -4.14 Q3 '25: -2.27 Q4 '25: -0.76 Q1 '26: -0.79 Q2 '26: -0.27 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.